Readership
Academics, Clinicians, Industrial Scientists, Ophthalmologists, Optometrists, Pharmacologists, Researchers, Residents
Scope
Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines ophthalmology and pharmacology to enable optimal treatment, prevention, and diagnosis of ocular diseases and disorders. It presents the latest in the ophthalmic drug discovery, delivery, and product development, emphasizing biopharmaceutics, pharmacokinetics, pharmacodynamics, and mechanisms of drug action.
Journal of Ocular Pharmacology and Therapeutics coverage includes:
- Drug discovery and development
- Mechanisms of drug action
- Drug delivery, nanomedicine, and nanotechnology
- Biopharmaceutics, pharmacokinetics, pharmacodynamics, and mathematical modeling
- Drug transporters and drug metabolism
- Pre-clinical and early-stage clinical trial results
- Gene and cell-based therapies
- Combination products
- Ocular pharmacotherapy/clinical trials/biomarkers
- Ocular toxicology and toxicokinetics
- Dry eye and ocular surface diseases
- Corneal diseases
- Glaucoma and optic neuropathies
- Retinal diseases
- Lens and cataract
- Ocular infection and trauma
- Ocular inflammatory and immune disorders
- Ocular ischemia and blood flow
- Ocular metabolic disorders
- Ocular pain
- Oculomotor complications
- Proliferative disorders of the eye
- Therapeutics for myopia and refractive errors
- Therapeutics for strabismus, ambylopia, and visual processing
- Eyes on New Product Development — written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA